AACR 2024 | Can ctDNA guide the treatment decision making process in melanoma?

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of the emerging role of circulating tumor DNA (ctDNA) in the management of melanoma. Since BRAF mutations occur in approximately half of patients with cutaneous melanoma, ctDNA can have widespread applications, and can assist in patient selection for clinical trials in the adjuvant setting. ctDNA can additionally help clinicians sequence treatments for patients with advanced melanoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.